The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (statins) on coronary events have generally been attributed to their …

Statins, which have been introduced to the clinic for the treatment of hypercholesterolemia,
are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase …

Abstract β-Hydroxy-β-methylglutaryl coA reductase inhibitors (HRIs) inhibit isoprenylation of
several members of the Ras superfamily of proteins and therefore have important cellular …

Background & Aims: Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase blocks the mevalonate metabolic pathway, which is necessary for the …

Several studies have demonstrated that any beneficial effect of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events are linked to their …

The advent of statin therapy has revolutionized the ability of the clinician to manage patients
at risk for the development of an ischemic event due to dyslipidemia. Large-scale clinical …

It is well established that 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (“statins”) reduce cholesterol levels and prevent coronary heart disease (CHD) …

Cancer cell adhesion confers a transient, de novo drug-resistant phenotype referred to as
cell adhesion-mediated drug resistance (CAM-DR). In this report, we extend the CAM-DR …

Background Experimental evidence suggests that statins protect against breast
carcinogenesis by interrupting cell cycle progression and promoting apoptosis. Evidence in …

Lovastatin is an irreversible inhibitor of HMG-CoA reductase and blocks the production of
mevalonate, a critical compound in the production of cholesterol and isoprenoids …